142 related articles for article (PubMed ID: 38123137)
41. Profound thrombocytopenia and survival of hematopoietic stem cell transplant patients without clinically significant bleeding, using prophylactic platelet transfusion triggers of 10 x 10(9) or 20 x 10(9) per L.
Nevo S; Fuller AK; Zahurak ML; Hartley E; Borinsky ME; Vogelsang GB
Transfusion; 2007 Sep; 47(9):1700-9. PubMed ID: 17725737
[TBL] [Abstract][Full Text] [Related]
42. Efficacy of tranexamic acid for the prevention of bleeding in patients with von Willebrand disease and Glanzmann thrombasthenia: a controlled, before and after trial.
Eghbali A; Melikof L; Taherahmadi H; Bagheri B
Haemophilia; 2016 Sep; 22(5):e423-6. PubMed ID: 27478149
[TBL] [Abstract][Full Text] [Related]
43. Prognostic Significance of Platelet Recovery in Myelodysplastic Syndromes With Severe Thrombocytopenia.
Tang Y; Zhang X; Han S; Chu T; Qi J; Wang H; Tang X; Qiu H; Fu C; Ruan C; Wu D; Han Y
Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):217S-222S. PubMed ID: 30296835
[TBL] [Abstract][Full Text] [Related]
44. Peridischarge prophylactic platelet transfusions after stem cell transplant: is a tranfusion trigger needed?
Meehan KR; Sharma P; McKenna DR; Dunbar NM
Transfusion; 2016 May; 56(5):1082-7. PubMed ID: 26867956
[TBL] [Abstract][Full Text] [Related]
45. Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia.
Estcourt LJ; Desborough M; Hopewell S; Doree C; Stanworth SJ
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011771. PubMed ID: 26627708
[TBL] [Abstract][Full Text] [Related]
46. Safety and cost effectiveness of a 10 x 10(9)/L trigger for prophylactic platelet transfusions compared with the traditional 20 x 10(9)/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia.
Wandt H; Frank M; Ehninger G; Schneider C; Brack N; Daoud A; Fackler-Schwalbe I; Fischer J; Gäckle R; Geer T; Harms P; Löffler B; Ohl S; Otremba B; Raab M; Schönrock-Nabulsi P; Strobel G; Winter R; Link H
Blood; 1998 May; 91(10):3601-6. PubMed ID: 9572994
[TBL] [Abstract][Full Text] [Related]
47. Immune-mediated platelet transfusion refractoriness in a severely thrombocytopenic patient with myelodysplastic syndrome successfully treated with romiplostim.
Krečak I; Skorić I; Čengić M; Krečak F; Skelin M
Transfus Apher Sci; 2023 Apr; 62(2):103582. PubMed ID: 36253251
[TBL] [Abstract][Full Text] [Related]
48. Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.
Desborough M; Estcourt LJ; Doree C; Trivella M; Hopewell S; Stanworth SJ; Murphy MF
Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010982. PubMed ID: 27548292
[TBL] [Abstract][Full Text] [Related]
49. Characteristics and Outcomes of Liver Transplantation Recipients after Tranexamic Acid Treatment and Platelet Transfusion: A Retrospective Single-Centre Experience.
Alsabani MH; Sibai A; Alharbi SF; Olayan LH; Samman AA; Al Harbi MK
Medicina (Kaunas); 2023 Jan; 59(2):. PubMed ID: 36837421
[No Abstract] [Full Text] [Related]
50. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
Li W; Morrone K; Kambhampati S; Will B; Steidl U; Verma A
Leukemia; 2016 Mar; 30(3):536-44. PubMed ID: 26500138
[TBL] [Abstract][Full Text] [Related]
51. Thrombopoiesis-stimulating agents and myelodysplastic syndromes.
Brierley CK; Steensma DP
Br J Haematol; 2015 May; 169(3):309-23. PubMed ID: 25659186
[TBL] [Abstract][Full Text] [Related]
52. Platelet mass index: is it a hope for reduction of platelet transfusion in NICU?
Yavuzcan Öztürk D; Erçin S; Gürsoy T; Karatekın G; Ovalı F
J Matern Fetal Neonatal Med; 2016; 29(12):1926-9. PubMed ID: 26169711
[TBL] [Abstract][Full Text] [Related]
53. Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions.
Ben-Bassat I; Douer D; Ramot B
Eur J Haematol; 1990 Aug; 45(2):86-9. PubMed ID: 2209824
[TBL] [Abstract][Full Text] [Related]
54. Evaluation of Military Use of Tranexamic Acid and Associated Thromboembolic Events.
Johnston LR; Rodriguez CJ; Elster EA; Bradley MJ
JAMA Surg; 2018 Feb; 153(2):169-175. PubMed ID: 29071337
[TBL] [Abstract][Full Text] [Related]
55. Prospective observational study of low thresholds for platelet transfusion in adult dengue patients.
Thomas L; Kaidomar S; Kerob-Bauchet B; Moravie V; Brouste Y; King JP; Schmitt S; Besnier F; Abel S; Mehdaoui H; Plumelle Y; Najioullah F; Fonteau C; Richard P; Césaire R; Cabié A
Transfusion; 2009 Jul; 49(7):1400-11. PubMed ID: 19320862
[TBL] [Abstract][Full Text] [Related]
56. An audit of platelet transfusion within the Wellington Cancer Centre.
Buhrkuhl DC; Karlsson MK; Carter JM
Intern Med J; 2012 Jan; 42(1):65-70. PubMed ID: 21040321
[TBL] [Abstract][Full Text] [Related]
57. Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.
Kantarjian H; Fenaux P; Sekeres MA; Becker PS; Boruchov A; Bowen D; Hellstrom-Lindberg E; Larson RA; Lyons RM; Muus P; Shammo J; Siegel R; Hu K; Franklin J; Berger DP
J Clin Oncol; 2010 Jan; 28(3):437-44. PubMed ID: 20008626
[TBL] [Abstract][Full Text] [Related]
58. The CRASH-2 trial: a randomised controlled trial and economic evaluation of the effects of tranexamic acid on death, vascular occlusive events and transfusion requirement in bleeding trauma patients.
Roberts I; Shakur H; Coats T; Hunt B; Balogun E; Barnetson L; Cook L; Kawahara T; Perel P; Prieto-Merino D; Ramos M; Cairns J; Guerriero C
Health Technol Assess; 2013 Mar; 17(10):1-79. PubMed ID: 23477634
[TBL] [Abstract][Full Text] [Related]
59. Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Platzbecker U; Wong RS; Verma A; Abboud C; Araujo S; Chiou TJ; Feigert J; Yeh SP; Götze K; Gorin NC; Greenberg P; Kambhampati S; Kim YJ; Lee JH; Lyons R; Ruggeri M; Santini V; Cheng G; Jang JH; Chen CY; Johnson B; Bennett J; Mannino F; Kamel YM; Stone N; Dougherty S; Chan G; Giagounidis A
Lancet Haematol; 2015 Oct; 2(10):e417-26. PubMed ID: 26686043
[TBL] [Abstract][Full Text] [Related]
60. The clinical impact of platelet refractoriness: correlation with bleeding and survival.
Kerkhoffs JL; Eikenboom JC; van de Watering LM; van Wordragen-Vlaswinkel RJ; Wijermans PW; Brand A
Transfusion; 2008 Sep; 48(9):1959-65. PubMed ID: 18564396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
